| Oct 3 |
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 30 |
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
|
| Sep 30 |
High Growth Tech Stocks To Watch For Future Potential
|
| Sep 25 |
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
|
| Sep 25 |
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
|
| Sep 18 |
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
|
| Sep 18 |
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
|
| Sep 18 |
Incyte downgraded at Truist on Jakafi patent cliff
|
| Sep 18 |
Update: Truist Securities Downgrades Incyte to Hold From Buy, Cuts Price Target to $74 From $83
|
| Sep 16 |
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
|
